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trials that support the utility, if not the effi cacy, of various forms of psychodynamic psychotherapy for treatment of patients with a wide range of DSM-IV axis I and II psychiatric disorders. Although each of these meta-analyses attempts, in its own way, to make use only of studies that are considered of high enough quality to warrant inclusion in a meta-analysis, there is sharp disagreement in the fi eld about whether the quality and number of studies included is suffi cient to warrant the conclusions drawn.
Ambiguity about the state of psychodynamic empirical research presents a signifi cant problem for training and practice in the mental health fi elds. The objective evaluation of the quality of randomized controlled trials of psychodynamic psychotherapy is a cogent place to begin the process of correcting this problem. Such trials are widely accepted in medicine as the gold standard for assessing treatment effi cacy, and there is good conceptual agreement about what constitutes a well-conducted trial (13) . The CONSORT (Consolidated Standards of Reporting Trials) Statement, which has been adopted by most major medical journals, identifi es 22 elements that are
The depth and quality of the evidence base for psychodynamic psychotherapy has long been a subject of controversy among psychodynamic and nonpsychodynamic clinicians and researchers. Some have argued that the relative absence of randomized controlled trials has doomed psychodynamic treatments to obsolescence (1) . This argument is sometimes used to support the further marginalization or even elimination of training in psychodynamic techniques in psychiatry, psychology, and social work training programs, to be replaced by "evidencebased treatments" (2) .
Others have argued that a body of empirical evidence for psychodynamic treatments exists and is underappreciated in the context of contemporary emphasis on shortterm, manualized, and symptom-focused treatments and targeted medications (3) (4) (5) . Over the past several years, meta-analyses have appeared in mainstream research outlets that argue for the effi cacy of psychodynamic treatments for specifi c disorders (6) (7) (8) (9) (10) (11) . Gabbard et al. (12) describe a "hierarchy of evidence" ranging from case studies and uncontrolled trials to randomized controlled 39 comparisons of a psychodynamic treatment and an "active" comparator, six showed dynamic treatment to be superior, fi ve showed dynamic treatment to be inferior, and 28 showed no difference (few of which were powered for equivalence). Of 24 adequate comparisons of psychodynamic psychotherapy with an "inactive" comparator, 18 found dynamic treatment to be superior.
Conclusions:
Existing randomized controlled trials of psychodynamic psychotherapy are promising but mostly show superiority of psychodynamic psychotherapy to an inactive comparator. This would be suffi cient to make psychodynamic psychotherapy an "empirically validated" treatment (per American Psychological Association Division 12 standards) only if further randomized controlled trials of adequate quality and sample size replicated fi ndings of existing positive trials for specifi c disorders. We do not yet know what will emerge when other psychotherapies are subjected to this form of quality-based review.
to more rigorous implementation in the 1990s and 2000s; 2) that some aspects of psychodynamic psychotherapy trials, including characterization of patients, reliable and valid measurement of outcome, and manualization of treatment, are now being done quite well; and 3) that some aspects of psychodynamic psychotherapy trials, including reporting of therapist training and supervision, measurement of treatment adherence, analysis of therapist or study site effects, and reporting of concurrent treatments and adverse events during treatment, remain lacking.
Method

Sample
We conducted a MEDLINE search to locate all published randomized controlled trials of psychotherapies identifi ed by their authors as being "psychodynamic" or "psychoanalytic." We also used meta-analyses and review articles to identify trials (6, (8) (9) (10) (11) (16) (17) (18) (19) (20) (21) (22) , examined the reference lists of recovered articles, and consulted experts in the fi eld to ensure that we obtained a comprehensive list. All studies that randomized participants to two or more treatments, one of which was identifi ed as "psychodynamic" or "psychoanalytic" treatment, were included. Studies that identifi ed themselves as precursors to larger and more complete studies were excluded even if randomization was performed. To capture the full range of study quality, we did not use a sample size cutoff in selecting trials. Only studies with published articles in English were included. A total of 94 trials were identifi ed that met inclusion and exclusion criteria.
Quality Measure: The RCT-PQRS
Items for the RCT-PQRS were generated by expert consensus. The experts included the subcommittee and several outside consultants, all of whom were senior psychotherapy or pharmacotherapy researchers. Contributors included those with experience in performing studies of psychodynamic psychotherapy, CBT, pharmacotherapy, and combinations. Items were compared with those of the CONSORT standard as well as several other measures of quality of outcome trials to ensure that all major domains for assessing study adequacy were included (13, 14, (23) (24) (25) (26) .
The RCT-PQRS consists of 25 items (Figure 1 ) corresponding to elements of study design, execution, and reporting, each rated 0 (poor description, execution, or justifi cation of a design elemen t), 1 (brief description or either a good description or an appropriate method/criteria but not both), or 2 (well described, executed, and, where necessary, justifi ed design element). Item 25, an "omnibus" item, was rated from 1 (exceptionally poor study) to 7 (exceptionally good study). Because of the complex scientifi c choices involved in determining study design, the measure was designed to be administered by individuals experienced in reading and conducting psychotherapy outcome trials.
Items were chosen so as to represent randomized controlled trial design and description elements that are crucial to the execution of a study that can be expected to yield reliable, valid, and reproducible data. No assumptions were made about whether individual design elements are already commonly implemented in such trials. In fact, several items were specifi cally chosen with the knowledge that they are not common practice (e.g., item 13, reporting of safety and adverse events) but with the conviction that they should be a standard part of psychotherapy randomized controlled trial methodology. No a priori assumptions were made about the relative importance of different items for the overall quality of the trial.
We calculated a total score by computing the nonweighted sum of the fi rst 24 individual items. Although we investigated both the important in reporting randomized controlled trials (14) . However, the CONSORT checklist and other similar measures, designed primarily to assess studies of pharmacological or medical interventions, fail to adequately assess the psychotherapy literature for several reasons. First, they do not include items that are specifi c and essential to psychotherapy trials, such as the length of follow-up or the extent of training or supervision of psychotherapy. Second, they focus on the quality of description in the written article, with less explicit focus on what was done in the actual trial, thus deemphasizing such essential details as assessment of adherence to the treatment actually delivered. Third, they pay insuffi cient attention to the quality and credibility of comparison treatments, as this is less of an issue for studies using pill placebo for the comparison group. And fourth, psychometric evaluation of CONSORT items has never been reported, nor have the items been used to quantify overall quality scores. An extension of the CONSORT Statement to randomized trials of nonpharmacological treatment (including, for example, surgery, technical interventions, devices, rehabilitation, psychotherapy, and behavioral intervention) published in 2008 consists of further elaboration of 11 of the checklist items, addition of one item, and modifi cation of the fl ow diagram (15) . Although helpful, this extension remains nonspecifi c to psychotherapy, focuses on description over conduct of the trials, and lacks psychometric evaluation.
As part of an effort to clarify the state of psychodynamic psychotherapy research, the Ad Hoc Subcommittee for Evaluation of the Evidence Base for Psychodynamic Psychotherapy (appointed in 2004 by the APA Committee on Research on Psychiatric Treatments) developed the Randomized Controlled Trial of Psychotherapy Quality Rating Scale (RCT-PQRS). This 25-item questionnaire was designed by experienced psychiatric and psychotherapy researchers from a variety of theoretical backgrounds as a systematic way to rate the quality of randomized controlled trials of psychotherapy. The scale is designed to be used by individuals with considerable experience in reading and executing psychotherapy trials but requires only 10 to 15 minutes to rate, in addition to the time spent reading the paper to which it is applied. The scale yields a 24-item total score that has good psychometric properties and captures the overall quality of design, implementation, and reporting of psychotherapy trials. (Item 25 is an omnibus item, more about which below.)
In this article, we report psychometric properties of the RCT-PQRS based on application of the scale to all 94 randomized controlled trials of individual and group psychodynamic psychotherapy published between 1974 and May 2010 that we were able to locate. We then describe the results of applying this measure to the psychodynamic outcome literature. Our hypotheses were 1) that the overall quality of randomized controlled trials of psychodynamic psychotherapy has improved over time, from a largely inadequate implementation in the 1970s and 1980s omnibus item and total scores, we believe that the fi rst 24 items are essential in guiding the thinking of the rater, and we did not intend to test the usefulness of a single item in the absence of a longer scale. The advantage of the total score is that it provides more variability and is explicitly based on 24 (relatively) independent judgments, whereas the advantage of the omnibus item is that it allows the rater to give relative weight to strengths or weaknesses of the study that he or she feels are particularly relevant (the sum arbitrarily weights all items equally). Therefore we intend to keep both metrics in our analyses. We estimated a priori that a total score of 24 would correspond to the minimum adequate total quality-of-study score, corresponding to an average value of 1 on each scale item. As this is the fi rst published use of the RCT-PQRS, no norms have yet been established. To illustrate the properties of the measure, we asked raters to score two well-known randomized controlled trials that are not included in this study (and do not include an explicitly psychodynamic treatment group). The National Institute of Mental Health Treatment of Depression Collaborative Research Program, which compared CBT, interpersonal psychotherapy, and medication, received a total quality score of 40 and an item 25 score of 6 (27) . The Treatment for Adolescents With Depression Study, which studied the effect of fl uoxetine, CBT, and their combination in depressed adolescents, received a total quality score of 38 and an item 25 score of 6 (28) . Both of these are believed to represent a high standard of quality for a randomized controlled trial of psychotherapy.
Method of Rating
For each of the psychodynamic trials identifi ed, a single published paper was selected that most thoroughly represented the methods and fi ndings of the study. Each study was then randomly assigned to one of fi ve senior raters (J.H.K., B.L.M., S.P.R., J.P.B., and M.E.T.). Each rater read the selected paper in its entirety and then completed the scale on the basis of the paper alone, disregarding prior knowledge that he or she may have had about the study. Raters were encouraged to go back to the paper during scoring to check on study details as needed. The reliability of these ratings has been described elsewhere (29) . Interrater reliability was assessed using the intraclass correlation coeffi cient (ICC) formula (ICC [1, 1] ) from Shrout and Fleiss (30) as implemented by the INTRACC.SAS procedure (31) using the STAT software package, version 9.1, of the SAS System for Windows (SAS Institute, Inc., Cary, N.C.). This formula is appropriate for a situation in which k (in this case, k=2) independent raters score each member of a sample but the identity of the raters changes at random from one member of the sample to the next. The internal consistency of the fi rst 24 items was assessed using the standard formula for Cronbach's alpha (32) . For the fi rst 70 studies included in this review, the total score ICC was 0.76 and Cronbach's alpha was 0.87. This indicates high interrater reliability of the total quality and high internal consistency of the items in the scale. For the purposes of this review, the rating of only a single senior rater was used for each study, as this is how the measure was designed to be used and is most likely how it will be used by other investigators.
The issue of whether raters were assessing the quality of the study itself or of the publication was an inevitable tension in data collection. Raters were instructed, for the sake of standardization and reliability, to base their ratings only on what was reported in the single article that was given to them. Whether a similar rule would be applied for future applications of this measure would depend on the resources and goals of the researchers. For this review, to collect and read all papers on a given study would have posed methodological challenges greater than those solved by using more than one paper per study (e.g., it would be hard to determine which publications were eligible and unfair to penalize studies that had generated fewer overall publications). However, raters were instructed to base ratings of items not only on the quality and inclusivity of the publication (although this was of a design element), 1 (brief description or either a good description or an appropriate method/criteria but not both), or 2 (well described, executed, and, where necessary, justifi ed design element). Item 25 is rated from 1 (exceptionally poor study) to 7 (exceptionally good study). 23 . Balance of allegiance to types of treatment by practitioners 24. Conclusions of study justified by sample, measures, and data analysis, as presented (note: useful to look at conclusions as stated in study abstract) 25. Omnibus rating: Please provide an overall rating of the quality of the study taking into account the adequacy of description, the quality of study design, data analysis, and justification of conclusions ajp.psychiatryonline.org AJP in Advance inevitably a signifi cant part of what guided their ratings) but also on the quality of the study design captured in these items and the extent to which convincing justifi cation was provided for design decisions whose rationale might not be entirely clear to someone familiar with the fi eld of psychotherapy research. Therefore, unlike the CONSORT standard, which is more instructive about a publication than about study design (although it clearly carries implications for the latter), the RCT-PQRS was intended to capture, as directly as possible, the quality of the study design.
Study Results and Comparator Type
We classifi ed the results of each study in terms of outcome at termination of treatment (psychodynamic psychotherapy compared with any other group in which a statistical comparison was reported). We rated whether the psychodynamic group did better, did the same, or did worse than the comparison group at the end of treatment based on statistically signifi cant results from primary outcome measures specifi ed by the authors (see the data supplement that accompanies the online edition of this article). When differences between groups were not statistically significant by the standards set by the study's authors, the comparison was placed in the "no difference" group. If the primary outcome measures were either insuffi ciently specifi ed or provided heterogeneous results, we rated the outcome category on the basis of the authors' summary of their fi ndings in the paper's abstract. We discussed any ambiguity about these ratings until a consensus was reached. For every paper, we felt that a clear and uncontroversial categorization could be reached.
Each comparison group was classifi ed as "active" or "inactive," following a distinction similar to that used by other authors (33) . An active comparison group is one that received a specifi ed treatment that has been validated by any previous empirical research for the disorder being treated or is considered a specifi c appropriate treatment by clinical consensus. This may include various forms of psychotherapy, as well as medication alone. For the purposes of this review, the standard for an active treatment was set intentionally low in order to capture the distinction between these treatments and those that are clearly intended by the investigators to be nonspecifi c and/or easy targets to beat (the inactive treatments). An inactive comparison group is any group that received no treatment at all (a no-treatment or waiting list control condition), treatment as usual, or a treatment that is not thought by any experts to be effective for the disorder being treated. Although Vinnars et al. (34) showed "treatment as usual" to be effi cacious for personality disorders, their research was conducted in Sweden, where strong, comprehensive universal health care with wellarticulated treatment descriptions for personality disorders is the national standard; therefore similar comparator groups were deemed "active." However, most of the studies reviewed here were conducted in the United States, where "treatment as usual" often represents little or no treatment. Furthermore, because by its very nature, "treatment as usual" is nonstandardized, it most often belongs in the "inactive" category for these purposes. We discussed any ambiguous classifi cations until consensus was reached and all authors agreed that each classifi cation was ultimately uncontroversial according to the standards specifi ed above.
Results
Study Characteristics
The 94 studies included in this analysis were from articles published in English between 1974 and May 2010. Total study sample size (combining patients from all treatment groups in a given randomized controlled trial) ranged from 10 to 487 (median=73). Seventy-two studies evaluated the effects of individual psychodynamic psychotherapy lasting less than 1 year, 12 studies looked at individual psychodynamic psychotherapy lasting 1 year or longer, and 17 studies were of psychodynamic group psychotherapy. There are no existing randomized controlled trials of psychoanalysis as currently defi ned by the American Psychoanalytic Association (minimal session frequency four times per week).
The number of comparison groups (excluding the group treated with psychodynamic psychotherapy) ranged from one to three (mean=1.4, SD=0.71). The frequencies of various types of comparison groups are presented in Table 1 . The most common comparison group was CBT (18 studies, 19%), followed by supportive therapy (11 studies, 12%). Contained within the 94 studies were 103 direct comparisons between psychodynamic psychotherapy and a nondynamic alternative treatment. Eleven studies did not report such a comparison (eight reported comparisons between two or more types of psychodynamic psychotherapy, and three failed to report comparisons of outcome at termination). Fourteen studies reported the results of separate comparisons between psychodynamic psychotherapy and two other treatments, and three studies reported comparisons with three other treatments. Of the 103 direct comparisons, 63 (61%) compared psychodynamic psychotherapy with an active treatment, and 40 (39%) compared psychodynamic psychotherapy with an inactive treatment.
The major diagnostic categories treated in the 94 studies are summarized in Table 2 . The most common diagnostic categories were depressive disorders (27%), personality disorders (14%), medical illness (11%), eating disorders (11%), anxiety disorders (10%), and substance abuse (7%). Because a wide range of methods were used for assessing the diagnostic category of the patients in these studies, subdividing the results of the review by diagnosis would result in combining across heterogeneous categories; meaningful results cannot be reported in terms of diagnostic categories.
Quality Scores
The methods used to standardize the RCT-PQRS and some initial results based on 69 of the randomized studies with a mean total quality of at least 24. Twenty-four (60%) of the 40 comparisons of psychodynamic psychotherapy and an inactive comparator came from studies with a mean total quality of at least 24.
Of the 63 comparisons between psychodynamic psychotherapy and an active comparator, six (10%) showed greater improvement in the psychodynamic group, 10 (16%) showed greater improvement in the comparator group, and the remainder (47 studies, 75%) showed no signifi cant difference between the groups. Of the 40 comparisons between psychodynamic psychotherapy and an inactive comparator, 27 (68%) showed greater improvement in the psychodynamic group, one (3%) showed greater improvement in the comparator group, and 12 (30%) showed no signifi cant difference between groups.
Associations Between Study Outcome and Quality
Mean total quality and item 25 scores were calculated separately for studies with active and inactive comparators that found signifi cant or no differences between groups at termination (Table 3) . No relationships were observed between quality of study and the nature of the comparator (active or inactive), between quality of study and the outcome of the comparison (dynamic therapy superior or inferior, or no difference), or between quality of study and an interaction of comparator type and outcome.
Sixty-three of the 103 comparisons described above had a total quality score of 24 or above (the cutoff for a "reasonably well done" study established from the face validity of the measure). Because some studies contain more than one comparison, these 63 comparisons represent controlled trials reviewed here have been described elsewhere (29) . An updated version of these fi ndings is summarized below. The overall quality score of the 94 studies was normally distributed, with a mean of 25.1 (SD=8.8; Figure 2) . More recently conducted studies had higher average total quality scores (29) . The omnibus item score (item 25) showed the same trend over time (29) . Individual item scores, although limited in their potential for interpretation because of the absence of high single-item interrater reliability, suggest the relative strengths and weaknesses of various study characteristics. For four of the 24 items, at least half of the studies were scored as "good" (i.e., a rating of 2): item 4 (description of numbers screened, included, and excluded), item 5 (treatment suffi ciently described or referenced), item 20 (comparison groups justifi ed by a priori hypotheses), and item 21 (comparison groups from same population and time frame). For three items, at least half of the studies were scored as "poor" (i.e., a rating of 0): item 13 (reporting of safety and adverse events), item 15 (intent-to-treat method reported in data analysis), and item 19 (consideration of therapist and study site effects). For 23 of 24 items, the mean item score was stable or increased across the time periods into which the studies were divided (1974-1988, 1989-1997, 1998-2004, 2005-2010) . The mean score of item 14 (long-term post-termination outcome assessment) increased between the fi rst two periods but then dropped and was lowest in the past 5 years, possibly refl ecting greater diffi culty in funding acquisition and acknowledgment of the inherent diffi culties in interpreting outcome data because of artifacts of intervening nonstudy interventions that increase over time.
Rater Effects
The mean total quality scores of the fi ve senior raters were 20.4, 24.1, 25.0, 25.4, and 27.0. For the three raters with psychodynamic orientations, the mean overall quality rating was 23.6 (SD=2.8), and for the two raters with a nondynamic orientation, the mean rating was 25.6 (SD=2.1). There was no signifi cant relationship between mean quality rating and theoretical orientation.
Study Outcome
In the sample of 94 outcome studies, we found a total of 103 comparisons between a psychodynamic treatment and a set of either inactive or active comparators. In studies with more than one active or more than one inactive comparator, we treated the comparisons within each set together because the fi ndings within a set of active or inactive almost always matched and because we did not want to improperly weight studies with more comparison groups in our analyses, as these studies tended to have smaller numbers of patients per group and were underpowered. Of the 103 comparisons, 63 were between psychodynamic psychotherapy and an active comparator and 40 were between psychodynamic psychotherapy and an inactive comparator. Thirty-nine (62%) of the 63 comparisons of psychodynamic psychotherapy and an active comparator came from ajp.psychiatryonline.org AJP in Advance treatment to be superior. When the total quality and item 25 scores of the higher-quality subgroup (63 studies) were analyzed with respect to outcome, no signifi cant differences were found between groups (Table 4) .
Discussion
In this evaluation, we examined a large amount of studyderived data collected to describe the utility of psychodynamic psychotherapy for psychiatric illness. On this basis, it appears that there is both good and bad news about the quality of randomized controlled trials of psychodynamic psychotherapy. The good news is that there are at least 94 randomized controlled trials published to date addressing the effi cacy of psychodynamic psychotherapy, spanning a range of diagnoses, and more than half of these (57%) are of adequate quality. The 94 studies represent 103 comparisons between the outcome of psychodynamic psychotherapy and a nondynamic comparator at termination. In the 50 of the original 94 studies. Four additional studies that were excluded from the list of comparisons (because they only compared psychodynamic therapies to each other or because they did not report outcome at termination) also had total quality scores of 24 or higher. Therefore, a total of 54 of the original 94 studies reviewed were deemed "reasonably well done" by this measure.
Thirty-nine of the 63 comparisons with adequate quality compared a dynamic treatment and an active comparator: six showed dynamic treatment to be superior, fi ve showed dynamic treatment to be inferior, and 28 showed no difference. Notably, 19 of the 24 active comparisons that were eliminated from this analysis because of a total quality below 24 came from the group that showed no difference between two treatments and the remaining fi ve came from the group that showed dynamic therapy to be inferior to a comparator. Twenty-four of the 63 higherquality comparisons looked at dynamic treatment against an "inactive" comparator, and 18 of these found dynamic 
FIGURE 2. Histogram of 24-Item Total Quality Scores for 94 Randomized Controlled Trials of Psychodynamic Psychotherapy
which a treatment is considered "evidence-based" for the purposes of inclusion in practice standards, educational curricula, or health care reimbursement vary widely. Perhaps the most commonly cited standard, fi rst published by Chambless and Hollon in 1996 from an American Psychological Association Division 12 (clinical psychology) task force (37) , requires at least two well-conducted trials using manuals, showing superiority or equivalence for a specifi c disorder, and performed by separate research groups, for a treatment to be considered "well-established." By this standard, the 25 high-quality trials reviewed could have been more than enough for psychodynamic psychotherapy to be considered "empirically validated." However, these 25 trials covered a wide range of diagnoses and used different manuals or forms of dynamic therapy. In addition, the signifi cant number of trials that failed to fi nd differences between dynamic and active or inactive comparators, most of which were not powered for equivalence, as well as a handful of trials that found dynamic therapies to be inferior to active comparators, suggest that more work is needed. It remains necessary to identify specifi c dynamic treatments that are empirically validated for specifi c disorders.
One fi nding of this review is that the clearest predictor of outcome from randomized trials of psychodynamic psychotherapy is whether or not the treatment was tested against an active or an inactive comparison treatment. We suspect that this fi nding is common to randomized controlled trials of all psychotherapies. There is no apparent relationship in this group of studies between study quality and the outcome measured in that study.
We have taken a highly critical view of data collected in support of psychodynamic psychotherapy in this evaluation. Few domains of psychiatric intervention have yet been evaluated so critically, and we emphasize that many domains of psychotherapy outcome research (i.e., CBT, cognitive-behavioral analysis system of psychotherapy, interpersonal psychotherapy, and supportive psychotherapy, to name some) may not fare signifi cantly better, despite the far greater number of outcome studies within these other domains to evaluate. We are currently embarking on a similar review of studies of CBT for depression. We believe that this is an appropriate stance, and we anticipate that this assessment can help move psychotherapy research in a direction toward better-designed outcome studies in the future. Thus far, proponents of other studied forms of specifi c psychotherapy, most notably CBT, have yet to dissect the quality of studies that support its effi cacy.
For three items in the RCT-PQRS, at least half of the studies were scored as "poor": item 13 (reporting of safety and adverse events), item 15 (intent-to-treat method reported in data analysis), and item 19 (consideration of therapist and study site effects). Individual item scores must be regarded with caution because we have not yet established a high degree of interrater reliability on individual items. However, we believe that all three of these 63 comparisons of dynamic treatment and an active comparator, dynamic treatment was found to be superior in almost 10% and inferior in 16%, and the analyses failed to fi nd a difference in almost 75%. In the 40 comparisons of dynamic treatment and an inactive comparator, dynamic treatment was superior in 68%, there was no evidence for difference in 30%, and dynamic treatment was inferior in one study. We obtained similar results if only studies of good quality are included. In comparisons of good quality studies involving dynamic treatment against an active comparator, dynamic treatment was superior in 15% and inferior in 13%, and evidence was lacking in either direction in 72%. In comparisons against an inactive treatment, dynamic treatment was superior in 75% and lacked evidence in either direction in 25%.
However, it is clear that there are signifi cant quality problems in a signifi cant percentage of randomized controlled trials of psychodynamic psychotherapy, and this may be true for trials of other psychotherapies as well. Based on the 94 studies reviewed here, reporting of safety and adverse events, intent-to-treat method in data analysis, and consideration of therapist and study site effects are lacking. Furthermore, 57% of all comparison and 54% of comparisons from studies of adequate quality failed to fi nd any statistical differences between outcome from psychodynamic treatment and a comparator. As Milrod (35) has pointed out, if a randomized controlled trial is not powered for equivalence (that is, lacks suffi cient enough power to detect differences between groups such that the absence of a signifi cant difference can be interpreted as equivalence in effi cacy or effectiveness of the treatments), it is impossible to conclude from the absence of a fi nding that dynamic treatment is as good as or not worse than the comparator treatment. In fact, if we use the rough approximation that a total sample size of at least 250 is required in order to be powered for equivalence (the actual number depends on the measures used), one of the comparisons reviewed here that failed to show a difference between psychodynamic treatment and an active comparator met that criterion (36) .
When considered from this perspective, an important fi nding is that of 63 statistical comparisons based on randomized controlled trials of adequate quality, six showed psychodynamic psychotherapy to be superior to an active comparator, 18 showed it to be superior to an inactive comparator, and one showed it to be equivalent to an active comparator. The empirical support for psychodynamic psychotherapy comes down to these 25 comparisons (in boldface in online data supplement). Most of the rest of even the trials of adequate quality are uninformative (33 studies), and several suggest that psychodynamic psychotherapy is worse than an active or inactive comparator (fi ve studies).
Therefore, it is our conclusion that although the overall results are promising, further high-quality and adequately powered randomized controlled trials of psychodynamic psychotherapy are urgently needed. The standards by ajp.psychiatryonline.org AJP in Advance it takes to learn and apply the measure and might not affect the overall scores. Third, we have not yet collected suffi cient data from the RCT-PQRS to study other ways of aggregating or weighting individual items. We anticipate performing the appropriate analyses as we collect data on a larger number and broader range of randomized controlled trials of psychotherapies. Finally, given that raters of the studies are not blind to study outcome or, in most cases, the allegiance of the study authors, the quality scale is theoretically susceptible to bias. Blinding the studies by removing the names of treatments or the direction of fi ndings would be diffi cult if not impossible, and the blinding process itself would be subject to biases. We addressed the potential for bias by making sure that our raters (and the designers of the scale) were drawn from a range of areas of clinical and research expertise, including pharmacotherapy, CBT, and psychodynamic psychotherapies. We observed no signifi cant relationship between quality ratings and theoretical orientation of raters. In fact, the mean total quality score was slightly lower for raters with a psychodynamic orientation than for those without. We hope that this better-operationalized evaluation of the quality of psychotherapy outcome studies will help guide investigators across all areas of psychotherapy research toward more scientifi cally credible, better-articulated research. Dr. Gerber has received support from NIMH, NARSAD, Eli Lilly (via the American Academy of Child and Adolescent Psychiatry Pilot Research Award), the American Psychoanalytic Association, the International Psychoanalytic Association, and the Neuropsychoanalysis Foundation. Dr. Kocsis has received grants and contracts from AstraZeneca, Burroughs Wellcome Trust, CNS Response, Forest, NIMH, the National Institute on Drug Abuse, Novartis, the Pritzker Consortium, Roche, and Sanofi -Aventis and serves on speakers bureaus or advisory boards for AstraZeneca, Merck, Pfi zer, and Wyeth. Dr. Milrod receives research support from NIMH and through a fund in the New York Community Trust established by DeWitt Wallace. Dr. Roose serves as a consultant to Forest, Medtronic, Wyeth, and Organon and receives research support from Forest. Dr. Barber has received grants from NIMH and the National Institute on Drug Abuse, medication support from Pfi zer for a randomized controlled trial on depression, and royalty income from Guilford Publications, Cambridge University Press, and Basic Books. Dr. Thase has served as a consultant or speaker for or received grant support from AstraZeneca, Bristol-Myers Squibb, Cephalon, Cyberonics, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica, Lundbeck, MedAvante, Neuronetics, NIMH, Novartis, Organon, Otsuka, Ortho-McNeil, PamLab, Pfi zer, Sanofi -Aventis, Schering-Plough, Sepracor, Shire US, Supernus Pharmceuticals, Transept, and Wyeth-Ayerst Laboratories; he has equity holdings in MedAvante and receives royalty income from American Psychiatric Publishing, Inc., Guilford Publications, Herald House, and W.W. Norton; he has provided expert testimony items represent signifi cant defi cits in the psychodynamic psychotherapy research literature that are still being insuffi ciently addressed (1) . It is well known by clinicians that all effi cacious treatments, whether they be psychotherapy or psychopharmacology, carry with them some risk of adverse effects, yet the randomized controlled trial literature in psychotherapy in general does not systematically report and discuss adverse events as do, for example, most good studies of medication (2) . While there has been signifi cant improvement in the area of intent-to-treat analysis, many randomized controlled trials of psychodynamic psychotherapy still focus primarily on "completer" analyses and do not adequately employ the intent-totreat method, which is a standard of the evidence-based medicine literature. Although intent-to-treat analyses also have certain limitations, they are the best starting point for addressing patient dropout in considering which treatments work best (38) (39) (40) . Finally, a large literature supports the importance of individual therapist and study site effects in psychotherapy outcome (41) (42) (43) , but the psychotherapy randomized controlled trial literature has not yet adequately responded by incorporating such considerations into a discussion of results, and even less into study design.
The RCT-PQRS focuses only on the reporting, execution, and justifi cation of design decisions made in a given report of a randomized controlled trial, but not on how these decisions affect the broader question of when results can be applied to real-world clinical practice. In other words, the measure addresses the importance of accurately and reliably quantifying the internal validity of a randomized controlled trial, while tracking generalizability less (3). As one example of this, the diagnostic categories described in Table 2 are just one conventional way of parsing the patient samples and are by no means the only way to subdivide these studies. None of the analyses in this article relied on diagnostic categories. However, future quality-based reviews and meta-analyses will need to address this issue.
The development and application of our quality measure have several signifi cant limitations. First, the accuracy of our ratings is necessarily limited by the extent of the information provided by the authors in their study descriptions. In some cases, the extent to which the authors describe a comparison treatment such as "treatment as usual" as active or inactive could have important consequences in rating the study. However, in our rating of active versus inactive comparator treatments, we observed no signifi cant differences between raters and therefore do not believe that there was much ambiguity in these ratings for the articles reviewed. Second, we have not yet developed and published a manual for the RCT-PQRS that would allow for greater single-item reliability across raters. Lack of reliability limits our ability to interpret individual item scores. Although a manual would likely improve item reliability, it would increase the time
